about
Familial cancer associated with a polymorphism in ARLTS1Management of elderly and unfit patients with chronic lymphocytic leukemia.Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience.Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working groupATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progressionA high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia.Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells.Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.Proliferative responses to PHA, anti-CD3 and antigens in patients with lymphoproliferative disease of granular lymphocytes. Mannoproteins of Candida albicans induce proliferation and cytotoxicity.Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility lociValidation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors.Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.Late listeriosis after fludarabine plus prednisone treatment.Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia.Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.Clinical relevance of silent red blood cell autoantibodies.Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases.Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia.Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
P50
Q28246251-1ADCC10B-CB8A-4812-BE79-1B7AD2B01CAAQ30243914-F39140A7-46E8-4CC2-90D1-C9CAF00F9C92Q33379988-4003A075-1E20-496B-AB84-1E8267EB4B2FQ33431829-C32349F3-A997-4B3E-B4C9-E235C218C353Q33707448-1DB5304E-56C7-4A5E-82F2-21EDF1B16CF1Q34543041-954A27F7-03C6-4EFA-B3DA-B8CEE1BE01ACQ35643020-BDB2F97D-242E-4FD0-895E-24B1170F551BQ36384877-D08AC7FC-B8EF-4B20-940D-97C35E4465B7Q36520447-3F1CFC1F-96DF-4A20-889A-C7F604C9327AQ36550468-B133FA7C-CD9C-4597-9A67-7BF5F797E62EQ38908415-B5A90E17-D509-4DC7-BCD2-3DCCB5490BF6Q39207331-2D72C65B-7B25-4BA1-B754-106A9282A968Q39592668-3C8B7759-C17D-4FC8-BF80-458512662E29Q40291554-3B7A5B33-EA1E-46C0-8F8D-D8CB4716E7F5Q40438184-E58C5A6D-4A58-4F85-895B-C119A6C43AF1Q40607052-55B2AA40-7F82-4C91-B67B-10EFD1AE60DEQ41138215-8196AE0E-6B0B-4627-AD7A-9639F477BCC9Q41481956-312FB6C1-7517-4BB7-BB63-6F05C8B6FC90Q41488936-E1BB1D46-E18C-4ECF-84D6-A07693EB90CBQ41880110-D3ADD150-5056-4183-881A-66BE8C0662FCQ42336286-DDA87CA0-AF8F-4F24-B8E4-96DD281DD11DQ42498048-E2B60601-3D1A-4827-803F-FEA378D5EF2DQ42627572-827C2756-CEC0-4B15-98E7-C1C04AAA65E8Q43207286-8D56C820-9B24-4E0E-9E15-A352A4255AC7Q44447816-C32648E9-F168-4EE9-A6EE-DDD2FB20B3FEQ44735422-44308614-EB94-4330-9EF3-E5603D44044BQ45106454-0CBBE18F-1A2C-403C-89D5-09813B45682BQ45181930-C663B765-110E-481C-A1C1-1219E9AA2A32Q45956089-3A7E91F6-D941-4788-9775-18FD38E9BD4AQ47094907-82D44983-634A-4439-B5FC-5FF937C331A6Q47160282-5A82A5E9-0037-428E-9F25-A982CEB5CD28Q47960638-2661C664-196A-4069-962D-30ADA2B850FCQ48370192-0449BAD7-04E1-4483-8381-E72A90954714Q49792155-9056AC09-7EC9-4791-9DA4-007A86489EF9Q50128112-13F791E6-029D-48A9-A0DF-C9656EECE440Q51544428-FB183D1F-4308-4333-89A4-2F46F9E96327Q51820016-A752432A-48DE-4A97-895D-182A74A947E9Q52333807-ECFFE6E5-749E-415B-ADD7-07DDD4D7A6EDQ52643368-7DE8FA47-4330-4F93-BDB0-373D49AE10F3Q52646820-5E642DF9-A251-4BCE-AD84-67A016D8B61C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesca Romana Mauro
@an
Francesca Romana Mauro
@ast
Francesca Romana Mauro
@br
Francesca Romana Mauro
@ca
Francesca Romana Mauro
@co
Francesca Romana Mauro
@da
Francesca Romana Mauro
@de
Francesca Romana Mauro
@en
Francesca Romana Mauro
@es
Francesca Romana Mauro
@eu
type
label
Francesca Romana Mauro
@an
Francesca Romana Mauro
@ast
Francesca Romana Mauro
@br
Francesca Romana Mauro
@ca
Francesca Romana Mauro
@co
Francesca Romana Mauro
@da
Francesca Romana Mauro
@de
Francesca Romana Mauro
@en
Francesca Romana Mauro
@es
Francesca Romana Mauro
@eu
prefLabel
Francesca Romana Mauro
@an
Francesca Romana Mauro
@ast
Francesca Romana Mauro
@br
Francesca Romana Mauro
@ca
Francesca Romana Mauro
@co
Francesca Romana Mauro
@da
Francesca Romana Mauro
@de
Francesca Romana Mauro
@en
Francesca Romana Mauro
@es
Francesca Romana Mauro
@eu
P106
P1153
7005890659
P21
P31
P496
0000-0003-2425-9474